Department of Urology, Guangdong and Shenzhen Key Laboratory of Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Shantou University Medical College, Shantou, Guangdong, China.
Int J Biol Markers. 2024 Mar;39(1):70-79. doi: 10.1177/03936155231213660. Epub 2023 Nov 13.
Globally, prostate cancer is the second most common malignancy in males. Serum microRNAs (miRNAs) may function as non-invasive and innovative biomarkers for various cancers. Our study aimed to determine potential miRNAs for prostate cancer screening.
A three-stage study was accomplished to ascertain crucial miRNAs as markers. In the screening stage, we searched PubMed for aberrantly expressed miRNAs relevant to prostate cancer and selected them as candidate miRNAs. In training and validation stages, with serum specimens from 112 prostate cancer patients and 112 healthy controls, expressions of candidate miRNAs were identified through quantitative reverse transcription-polymerase chain reaction. The diagnostic capabilities of miRNAs were determined by receiver operating characteristic curves. Bioinformatic analysis was utilized to explore the function of the critical miRNAs.
Expression of six serum miRNAs (miR-34b-3p, miR-556-5p, miR-200c-3p, miR-361-5p, miR-369-3p, miR-485-3p) were significantly altered in prostate cancer patients contrasted with healthy controls. The optimal combination of critical miRNAs is a three-miRNA panel (miR-34b-3p, miR-200c-3p, and miR-361-5p) with good diagnostic capability. FLRT2, KIAA1755, LDB3, and NTRK3 were identified as the potential genes targeted by the three-miRNA panel.
The three-miRNA panel may perform as an innovative and promising serum marker for prostate cancer screening.
在全球范围内，前列腺癌是男性中第二常见的恶性肿瘤。血清 microRNAs（miRNAs）可能作为各种癌症的非侵入性和创新生物标志物发挥作用。我们的研究旨在确定用于前列腺癌筛查的潜在 miRNAs。
完成了一个三阶段的研究，以确定关键的 miRNA 作为标志物。在筛选阶段，我们在 PubMed 上搜索与前列腺癌相关的异常表达 miRNA，并将其选为候选 miRNA。在训练和验证阶段，我们使用来自 112 例前列腺癌患者和 112 例健康对照者的血清标本，通过定量逆转录-聚合酶链反应鉴定候选 miRNA 的表达。通过接收者操作特征曲线确定 miRNA 的诊断能力。利用生物信息学分析探索关键 miRNA 的功能。
与健康对照者相比，前列腺癌患者血清中六种 miRNA（miR-34b-3p、miR-556-5p、miR-200c-3p、miR-361-5p、miR-369-3p、miR-485-3p）的表达明显改变。关键 miRNA 的最佳组合是一个三 miRNA 组合（miR-34b-3p、miR-200c-3p 和 miR-361-5p），具有良好的诊断能力。FLRT2、KIAA1755、LDB3 和 NTRK3 被鉴定为三 miRNA 组合靶向的潜在基因。
三 miRNA 组合可能作为一种创新和有前途的用于前列腺癌筛查的血清标志物。
Zotero 插件